Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Rhea-AI Summary
Glucotrack (Nasdaq: GCTK) published a peer-reviewed Journal of Diabetes Research study reporting long-term accuracy and stability of its fully implantable continuous blood glucose monitor in an in-vivo ovine model.
The study implanted 34 devices in 17 sheep for up to 240 days, reporting a weighted average MARD 6.8%, consistent sensing, and no device-related adverse safety events; company also cites first-in-human MARD 7.7% with 99% data capture.
Positive
- MARD 6.8% measured across 79 IVGTTs in ovine study
- Devices maintained consistent sensing for up to 240 days in vivo
- No device-related adverse safety events observed in the ovine study
- First-in-human MARD 7.7% with 99% data capture cited
Negative
- Findings are preclinical in an ovine model; human performance may differ
- IDE submission with FDA is described as ongoing; IDE clearance not yet achieved
News Market Reaction – GCTK
In the Apr 30 session, GCTK declined 7.26%, reflecting a notable negative market reaction. Argus tracked a trough of -13.0% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | Peer-reviewed study | Positive | -4.0% | Publication on long-life sensor design supporting multiyear implantable CBGM feasibility. |
| Mar 30 | Earnings report | Positive | -14.1% | 2025 financials, new patents, private placement, and IDE filing and trial timing plans. |
| Mar 27 | IDE planning | Positive | -9.2% | Plan to file IDE in Q2 2026 backed by Brazil and Australia study data. |
| Mar 10 | Conference presentation | Positive | -2.4% | LSI USA ’26 presentation highlighting CBGM technology and U.S. commercialization plans. |
| Jan 29 | Patent issuance | Positive | -33.4% | USPTO issuance of three patents covering sensor chemistry and device design. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent historically positive milestones for Glucotrack have often been followed by negative 24-hour price reactions, suggesting a pattern of selling into good news.
Over the past six months, Glucotrack has reported multiple milestones around its implantable CBGM platform, including USPTO patent issuances on Oct–Nov 2025, IDE planning and trial updates in Q1 2026, and prior peer‑reviewed publications on long‑life sensor design (Apr 7, 2026). Despite generally constructive clinical, regulatory, and IP progress, each of these five news events saw negative 24‑hour price reactions, indicating repeated divergence between fundamentally positive updates and short‑term trading behavior leading into today’s publication.
Key Terms
continuous blood glucose monitoring medical
cbgm medical
in-vivo medical
intravascular medical
intravenous glucose tolerance tests medical
mean absolute relative difference medical
mard medical
investigational device exemption regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE Submission
RUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company’s fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model.
The study, titled “In Vivo Evaluation of a Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack™ Inc. Investigation,” (Tapsak, M. A. et al.), evaluated the in-vivo performance of the CBGM in an ovine model over periods of up to 240 days. The study examined 34 devices that were successfully implanted into 17 adult sheep. Results demonstrated a weighted average Mean Absolute Relative Difference (MARD) of
“The publication of this peer-reviewed study in the Journal of Diabetes Research provides externally validated evidence of the long-term performance of our CBGM technology,” said Dr. Paul V. Goode, President and Chief Executive Officer of Glucotrack. “Sustained accuracy and consistent device performance over 240 days in a preclinical model reinforces our confidence in the platform’s design. As we advance towards our IDE submission with the FDA, these results support our continued progression toward further clinical development and eventual commercialization.”
These data further support the accuracy and stability of Glucotrack’s CBGM system, which demonstrated a MARD of
For more information about Glucotrack's CBGM, visit www.glucotrack.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contacts:
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
